Par Pharma Begins Shipping Generic Atacand HCT
Tickers: AZN
Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca (NYSE: AZN) to distribute the authorized generic version of AstraZeneca's Atacand HCT^® (candesartan cilexetil/hydrochlorothiazide). Par has begun shipping 16/12.5 mg, 32/12.5 mg and 32/25 mg strengths of candesartan cilexetil/ hydrochlorothiazide tablets. According to IMS Health data, annual U.S. sales of Atacand HCT^® are approximately $61 million.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted in: News